Skip to content

Cellebrite

US · CLBT #2562 by market cap Listed 1970
10.77 -0.55 -4.86%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Valuation each multiple against its own 5-year range

P/B ratio 5.00 Cheap vs history 24th percentile
5-year average 8.13 · #108 of 156 in Software - Infrastructure
P/E ratio 46.12 Expensive vs history 82nd percentile
5-year average 3.23 · forward 35.06 · #58 of 83 in Software - Infrastructure
P/S ratio 5.39 In line with history 42nd percentile
5-year average 6.19 · forward 4.77 · #117 of 175 in Software - Infrastructure

Vs. peers Software - Infrastructure

Company Market cap P/E (TTM) P/B Div yield
Cellebrite (CLBT) 2.71B 43.08 4.67 0.00%
Microsoft (MSFT) 3.60T 25.30 7.65 0.75%
Palantir (PLTR) 345.74B 101.05 30.79 0.00%
Oracle (ORCL) 305.97B 15.86 4.95 1.98%
Palo Alto Networks (PANW) 281.87B 686.64 9.83 0.00%
CrowdStrike (CRWD) 234.93B 6,037.89 46.05 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value14.05 Economic moatNarrow UncertaintyMedium

Trading 30.5% below Morningstar's fair value estimate.

Fair value

Given the significant price pressure over the last year, Cellebrite DI Ltd might appear cheap. However, to account for the possibility that it may be a value trap, we've restricted its rating to 3 stars. The stock currently trades at a 18% discount to our quantitative fair value estimate of $14.05 per share; however, some caution is warranted due to this estimate's medium uncertainty rating.

The company's solid growth bolsters our quantitative valuation. Consistent revenue and earnings growth indicates a company's potential for increased market share and profitability. For example, the firm's revenue 3-year growth of 20.6% sits in the top 20% compared with peers globally. Robust trailing three-year revenue growth portends a favorable future trajectory, which contributes to our view that shares are cheap.

On a different note, the firm's valuation metrics are potentially concerning. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's book value yield of 17.2%, for example, sits in the bottom 20% globally. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which, despite our favorable price/fair value ratio, is a negative attribute.

Economic moat

The company's narrow quantitative moat rating indicates it could outearn its cost of capital and maintain robust margins for 10 years or longer. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Cellebrite discussion 0 comments

Add a comment